Board of Directors

Ms. Catherine Coste has served as a Director of the Company since September 2020.  Ms. Coste retired from Deloitte and Touche LLP in 2020, where she was a senior partner and served as one of Deloitte’s Life Sciences Industry Executive Leader. She spent 32 years in both corporate and professional services positions leading global finance, internal audit and operations teams. During her career at Deloitte, Ms. Coste was directly involved with over 30 life science corporations, the majority of which were large-cap and medium-cap public corporations. She also serves as a Director at both Minerva Surgical, Inc., where she is Chair of the Audit Committee and a Member of the Compensation Committee, and Renalytix, plc, where she is Chair of the Audit Committee and a Member of the Renumeration Committee.  Ms. Coste also has extensive experience in Sarbanes-Oxley compliance, corporate risk analysis and management, cyber risk assessment, fraud prevention, IT systems analysis and upgrades, internal controls and corporate governance. Ms. Coste is a Certified Public Accountant in California.

Has served as a Director of the Company since April 2007. Since July 1, 2009, Dr. Emerson has served as Vice Chair for Clinical Programs and Chief of Clinical Pathology at the University of Southern California Keck School of Medicine, Los Angeles, California. From 1994 to 2009, Dr. Emerson was on the faculty of the University of California, Irvine School of Medicines where she served as Chief of Clinical Pathology and from 2000 to 2009, also served as the Vice Chair for Clinical Programs, Department of Pathology and Laboratory Medicine.

Mr. David Moatazedi has served as the President and Chief Executive Officer, and as a member of the of Board of Directors of Evolus, Inc. (NASDAQ: EOLS), since May 2018. Evolus is a publicly traded life sciences company headquartered in Orange County, California, with a market capitalization of approximate $500 million.  From March 2017 to June 2020, David also served as an independent board member of Obalon Therapeutics, a publicly traded life sciences company that was later merged into ReShape Lifesciences Inc.  From 2016 to 2018, David served as Senior Vice President at Allergan Inc. (“Allergan”), and division head of the U.S. Medical Aesthetics division. Prior to Evolus, Mr. Moatazedi worked in various other leadership positions within Allergan since 2005, including Vice President, Sales and Marketing of the U.S. Facial Aesthetics and the U.S. Plastic Surgery Divisions.  Before Allergan, Mr. Moatazedi was a district manager for Novartis Pharmaceuticals. Mr. Moatazedi holds, an M.B.A. from Pepperdine University and a B.A. from California State University, Long Beach.

Mr. Kenny has over 30 years of operational and commercial leadership experience.  In addition to serving on the Board at Biomerica, Mr. Kenny is also a current independent member of the Board of Directors for Quantum Si (QSI: Nasdaq).  Mr. Kenny previously served as Meridian Bioscience’s Chief Executive Officer and on the Meridian Board of Directors. He joined Meridian Bioscience (a life science and diagnostic company) in October 2017 and led the business turnaround resulting in the company’s sale in January 2023 (to SJL Partners and SD Biosensor).   Before his tenure at Meridian, Mr. Kenny served as Senior Vice President and General Manager, North America, with Siemens Healthcare from 2014 to May 2017. From 2012 – 2014, Mr. Kenny served as Vice President and General Manager, U.S. Region, for Becton Dickinson, Diagnostic Systems. Prior to 2012, he held executive roles at Danaher Corporation and Quest Diagnostics. Mr. Kenny’s operational experience as a CEO of a publicly traded company, along with his key executive leadership within large public companies in the health care and medical device industry, makes him a valuable member of the board.